BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD

Published: 8-Dec-2023
Research & Development

Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for a total value of 28 MUSD to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects

The project is estimated to run from late Q4 2023 until Q1 2026 and the platform is aimed to shorten time for drug development workflows. The project will run in a ramp-up phase during 2024 and the vast majority of the project will be carried out and invoiced during 2025.
 
“This agreement is a milestone for the Group and it’s our largest project to date. It also shows the strength in Biosero’s offering for laboratory automation solutions and we expect to shorten current timelines for drug development through automation”, says Maria Forss, President and CEO, BICO.

See more

You may also like

Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Read more
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing

Trending Articles

  1. Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
  2. Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
  3. L.B. Bohle hosts successful continuous manufacturing workshop in Brazil Focus on continuous wet granulation and drying for research, development and small-scale production
  4. AstraZeneca's tozorakimab meets primary endpoint in both Phase III COPD trials AstraZeneca has reported positive results from the OBERON and TITANIA Phase III trials, with tozorakimab significantly reducing moderate-to-severe COPD exacerbations compared to placebo
  5. From powder to granules: a deep dive into wet granulation methods - WEBINAR NOW ON DEMAND Join ACG in partnership with Manufacturing Chemist for an expert-led session to explore how different wet granulation methods impact consistency, yield, and quality — and what really matters when it comes to selecting and optimising your process

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Research & Development

Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption

A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing

Degasser for volatile and aggressive solvents

Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Research & Development

Symeres joins forces with Ambagon Therapeutics to expand molecular glue research in colorectal cancer

The pair will aim to explore a new class of small molecules, known as molecular glues, for potential therapeutic use in colorectal cancer and other hard-to-target diseases as an alternative to traditional therapies
Research & Development

University of Exeter leads £4.5m Wellcome-funded initiative to develop bioimaging tools for fungal pathogens

An international collaboration spanning the universities of Exeter, Edinburgh and Cape Town has secured £4.5m to develop specialist bioimaging tools for WHO-priority fungal pathogens
Subscribe now